HLS THERAPEUTICS INC.

Analyst Reco. HLS Therapeutics Inc.

Equities

HLS

CA40390B1094

Market Closed - Toronto S.E. Other stock markets 03:59:17 2024-05-22 pm EDT			5-day change	1st Jan Change
3.85 ^CAD	-1.28%		-3.02%	-2.53%

May. 09	Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HLS Therapeutics Downgraded to Hold at Stifel GMP on Revenue Concerns; Price Target Cut to C$5.00	Nov. 10	MT
HLS Therapeutics Buy Rating Maintained at Stifel GMP as Growth Expectations Eased; Price Target Cut to C$12.25	23-09-19	MT
HLS Therapeutics Brief: Announcing Updates to its Credit Agreement; Term Extended, Borrowing capacity increases, Financial flexibility improves, and Interest rates remain relatively unchanged	23-08-14	MT
HLS Therapeutics Buy Rating Reiterated at Stifel GMP as Vascepa Prescriptions Rise; Price Target Kept at C$26.00	22-12-13	MT
HLS Therapeutics Reiterated at Buy at Stifel GMP on Rising Sales; Price Target Kept at C$32.00	22-09-28	MT
HLS Therapeutics Keeps Buy Rating at Stifel GMP Following Q2 Results; Price Target Cut to C$32.00	22-08-12	MT
HLS Therapeutics Buy Rating Maintained by Stifel GMP as Vascepa Sales Expand	22-07-20	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

fermer